Prescribing patterns of antiplatelet drugs in patients with cardiovascular and cerebrovascular diseases

• Author Details:   
• Sumit Choudhary
• Anurag Kumar ^*
• Ravi Shankar Dwivedi
• Tushar Arora

---

View PDF

Background: Antiplatelet drugs play a crucial role in the management of the Cardiovascular and Cerebrovascular disease. This aim is to provide Evidence based treatment in the prevention of the worldwide health threat of this disease.
Objective: The Objectives is to assess the current prescribing practices of antiplatelet drugs for patients with cardiovascular and cerebrovascular diseases and to identify potential factors influencing prescribing patterns in patient with comorbidities.
Materials and Methods: At Superspeciality hospital, a 6-months cross sectional Prospective observational Research was conducted on impatient patient of Cardiology & Neurology Department,145 Prescription were examined and deemed inoperative.
Result: The study shows that cardiovascular and cerebrovascular diseases are more common in men (62.1%) than women (37.9%), with a sample of 90 males and 55 females. Cardiovascular diseases predominate over cerebrovascular diseases in both rural and urban areas, with a slightly higher incidence in urban populations. Young adults (18-30) have minimal risk, which increases with age, particularly among older adults; 11 individuals have both conditions. The most prescribed antiplatelet therapy is Aspirin and Ticagrelor (79.03%), followed by Aspirin and Clopidogrel (19.35%), with Clopidogrel and Aspirin Av being the least common (1.66%). A significant overlap of comorbidities (65%) is noted due to shared risk factors, and 78% of patients have a history of cardiovascular or cerebrovascular events. Patients with diabetes, CKD, and AKI are at higher risk for thrombotic and bleeding complications, requiring careful monitoring of antiplatelet therapy. In cases of hypothyroidism and pulmonary oedema, Aspirin is the most frequently used antiplatelet (49%), followed by Clopidogrel (20%), Ticagrelor (17%), and Prasugrel (12.4%).
Conclusion: The study provides valuable understanding of these disease, effectiveness of multiple antiplatelet therapies, & impact of comorbidities on the treatment option.